
Dr. Eng Breaks Down Braftovi Plus Erbitux FDA Approval in BRAF+ mCRC
In December 2024, the United States Food and Drug Administration (FDA) approved treatment with the combination of Braftovi (encorafenib) and Erbitux (cetuximab) plus chemotherapy for patients with metastatic colorectal cancer with a BRAF V600E mutation. …